ARVEE LABORATORIES (INDIA) LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 213.8 INR | +0.28% |
|
-4.72% | +23.59% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2022 | 403M 4.83M | Sales 2023 | 613M 7.35M | Capitalization | 970M 11.63M |
|---|---|---|---|---|---|
| Net income 2022 | 25M 300K | Net income 2023 | 41M 492K | EV / Sales 2022 | 3.07 x |
| Net cash position 2022 | 14.98M 180K | Net Debt 2023 | 1.08M 12.98K | EV / Sales 2023 | 1.58 x |
| P/E ratio 2022 |
48.7
x | P/E ratio 2023 |
23.5
x | Employees | 67 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 99% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.28% | ||
| 1 week | -4.72% | ||
| Current month | -4.72% | ||
| 1 month | +1.18% | ||
| 3 months | +37.20% | ||
| 6 months | +84.11% | ||
| Current year | +23.59% |
1 week
204.05
232.85
1 month
193.40315.00
Current year
117.05315.00
1 year
98.10315.00
3 years
62.90315.00
5 years
18.80315.00
10 years
18.80315.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 01/14/01 | |
| Director of Finance/CFO | - | 10/18/10 | |
| Compliance Officer | 32 | 15/19/15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 36 | 01/21/01 | |
| Chief Executive Officer | 50 | 01/14/01 | |
| Director/Board Member | 39 | 27/12/27 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/24/03 | 213.8 | +0.28% | 1,974 |
| 02/24/02 | 213.2 | -4.99% | 6,036 |
| 30/24/30 | 224.4 | -3.65% | 4,558 |
| 29/24/29 | 232.8 | +3.79% | 13,954 |
Delayed Quote NSE India S.E., May 03, 2024 at 05:13 pm IST
More quotes
Arvee Laboratories (India) Limited is an India-based company engaged in manufacturing of specialized chemicals. The Company's product categories include polymer modifiers, contrast media intermediates and drug intermediates. Its polymer modifiers products include Dimethyl 5-Sodiosulfoisophthalate, 5-Sulfoisophthalic Acid Mono Sodium Salt, 5-Sulfoisophthalic Acid Mono Lithium Salt and 5-Sodiosulfo-Bis-(B-Hydroxyethyl)-Isophthalate. The Company's contrast media intermediates products include 5-Nitroisophthalic acid, Dimethyl 5-Nitroisophthalate, Monomethyl 5-Nitroisophthalate, 5-Hydroxyisophthalic acid, 5-Aminoisophthalic acid, Dimethyl 5-Aminoisophthalate, and 3,5-Diamino Benzoic Acid. Its drug intermediates products include 2-Acetyl Thiophene, Thiophene-2-Carboxaldehyde, 4-Amino Pyridine and 2-Chloro-5-Nitrobenzoic Acid.
Sector
Diversified Chemicals
Calendar
30/05/2024
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +23.59% | 28.25M | |
| +1.22% | 78.18B | |
| +0.59% | 47.18B | |
| +0.96% | 32.47B | |
| +8.75% | 18.01B | |
| -9.28% | 11.74B | |
| +8.55% | 11.47B | |
| -2.33% | 10.43B | |
| +5.97% | 9.98B | |
| +3.48% | 9.12B |
- Stock Market
- Equities
- ARVEE Stock